Plasma-based IWR-1 solubility dmso diagnostics have revolutionized many facets of medicine, as exemplified by the use of troponins for the early diagnosis of acute myocardial infarction. On the other hand, plasma biomarkers may be confounded by extra-renal sources as well as

by subclinical changes in renal elimination. Thus, in the case of AKI, it is important and ideal to develop both urinary and plasma biomarkers. The majority of NGAL results described in the literature have been obtained using research-based ELISA assays that are currently available from commercial sources such as Bioporto (Gentofte, Denmark) and R&D Systems (Minneapolis, MN, USA). These assays are accurate, but are not practical in the clinical

setting. In these regards, a major advance has been the development of a point-of-care kit for the clinical measurement of plasma NGAL (Triage® NGAL Device, Biosite Incorporated, San Diego, CA, USA). In children undergoing cardiac surgery, the increase in plasma NGAL levels measured by the Triage® Device at various time points after cardiopulmonary bypass was proportional to the severity of AKI.66 In terms of diagnostic accuracy, the 2 h plasma NGAL measurement showed an AUC of 0.96, sensitivity of 0.84, and specificity of 0.94 for prediction of AKI using a cut-off value of 150 ng/mL.66 Several addition publications have now confirmed the utility and accuracy of the Triage® NGAL Device in critically ill adults.35–37,55,57 The assay is facile with quantitative click here results available in 15 min, requires only microlitre quantities of whole blood Meloxicam or plasma, and is currently being tested in multicentre trials for further validation. In addition, a urine NGAL immunoassay has been developed for a standardized clinical platform (ARCHITECT® analyzer, Abbott Diagnostics, Abbott Park, IL, USA). In children undergoing cardiac surgery, the increase in urine NGAL levels determined by ARCHITECT® analyzer at various time points after cardiopulmonary bypass was

also proportional to the severity of AKI.67 The 2 h urine NGAL showed an AUC of 0.95, sensitivity of 0.79, and specificity of 0.92 for prediction of AKI using a cut-off value of 150 mg/mL.67 This assay is also easy to perform with no manual pretreatment steps, a first result available within 35 min, and requires only 150 µL of urine. This assay is also currently undergoing multicentre validation in several clinical populations. The genesis and sources of plasma and urinary NGAL following AKI require further clarification. Although plasma NGAL is freely filtered by the glomerulus, it is largely reabsorbed in the proximal tubules by efficient megalin-dependent endocytosis.20 Direct evidence for this notion is derived from systemic injection of labelled NGAL, which becomes enriched in the proximal tubule but does not appear in the urine in animals.